In GBM there are basically almost no costs to market. All word of mouth to the small group of neuro oncologists most of whom are going to know about DCVax very soon if they are not aware yet. Off label use demand will be high once markers being matched to benefit is revealed. In other words demand will outstrip any need to market. Learning how biologics development works based on relationship to big money influence Is hard for wide eyed biotech investors to fathom especially when the vultures want to steal the tech and pick the bones of the little bios who never make it through the desert alive or unenslaved. There are very few true “White Knights” out there and fewer still who would take the time to understand this tech enough to invest large sums with confidence and with good motives to benefit all investors. Had that been the case for NWBO we might still have had to wait for regulators to catch up to the new treatment effect and acceptance of ways to measure it. Anyway, glad you found your way back and hope you can see the present opportunity as one much different than those of the past here. Best wishes.
I used to really like your observations back in the day. However, what you write now appears to be sour grapes. You seem perturbed that you may miss out on a truly amazing story. Bury the anger, and either get back in, or just let it go.
News 
Market Data 
Discover 
AI
